Contract drug manufacturing (CDMO) stocks

CDMO

What are Contract drug manufacturing (CDMO) stocks in Korea?

The Contract drug manufacturing (CDMO) theme on jonbur groups 24 Korean stocks listed on KOSPI and KOSDAQ, worth ₩127T in total. On Oct 27, 2026 the group moved down 3.11% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.

Stocks: 24
Total market value: ₩127T
Day's move: −3.11%
As of: Oct 27, 2026
Largest members: Samsung Biologics, Celltrion, Hanmi Pharm

Earnings tracker · 3Q 2026

Reporting season · reports due by Nov 14

4 of 24 reportedOperating profit up vs a year ago: 3 of 4

Revenue+29.1%

Operating profit+51.8%

Net profit−33.3%

Combined, for the companies that have reported, vs the same quarter a year ago

Company	Reported	Revenue	vs a year ago	Operating profit	vs a year ago	vs last quarter	Op. margin
Celltrion	Oct 12Preliminary	₩1.5T	+45.8%	₩510B	+69.2%	+12.9%	34.0%29.3%
Hanmi Pharm	Oct 27Preliminary	₩377B	+4.2%	₩38B	−31.3%	−71.2%	10.0%15.2%
ST Pharm	Oct 27Preliminary	₩98B	+19.1%	₩16B	+6.6%	−14.3%	16.1%18.0%
Dong-A ST	Oct 27Preliminary	₩207B	−4.4%	₩21B	+52.9%	+239.9%	10.4%6.5%
Samsung Biologics	Expected around Oct 28
SK Bioscience	Expected around Nov 3
GC Biopharma	Expected around Nov 3
Chong Kun Dang Pharmaceutical	Expected around Nov 3
IL Dong Pharmaceutical	Expected around Nov 6
Daewoong Pharma	Expected around Nov 7
Huons	Expected around Nov 10
GL Pharm Tech	Expected around Nov 10
Aprogen Biologics	Expected around Nov 13
SAM Chun Dang Pharm	Expected around Nov 14
Proteina	Expected around Nov 14
Samyang Holdings	Expected around Nov 14
Binex	Expected around Nov 14
BNC Korea	Expected around Nov 14
Kolon Life Science	Expected around Nov 14
Prestige Biologics	Expected around Nov 14
SeouLin Bioscience	Expected around Nov 14
Prestige BioPharma	Expected around Nov 28
Inventage Lab	Expected around Dec 1
BioInfra Life Science	Not yet

Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.

Technical breadth

After the close on Oct 27, 2026

Above 20-day average: 18.8%
Above 60-day average: 25%
RSI above 70: 0%
RSI below 30: 6.3%
52-week highs: 0
52-week lows: 4

Index gauge · Short term

Bearish

0 bullish, 2 neutral, 7 bearish

Index gauge · Medium term

Bearish

0 bullish, 1 neutral, 7 bearish

Technical read

The contract drug manufacturing (CDMO) theme covers 32 members, and only 18.8% of them trade above their 20-day average while 25% sit above their 60-day average. Breadth is weak on the trend measures, with no members at a 52-week high and 4 at a 52-week low, and the lowest member RSI reads 6.3 while the highest reads 0. The equal-weighted theme index is marked bearish on both short-term and medium-term readings, with an RSI of 38.8 and the index positioned below its cloud.

Written by AI from the indicator values above. Not advice.

Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.

Credit & macro

MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK Reit SK hynix SK Networks SK Discovery SKC SK Telecom